Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2024-04-25 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯2023年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and the responsibility of the company's board and auditors regarding internal control over financial reporting as of December 31, 2023. The document contains an auditor's opinion on the effectiveness of internal controls, which is typical of a standalone audit report rather than a full annual report or other filings. The length is 1289 characters, which is short but sufficient for an audit opinion. There is no indication that this is an announcement or a certification letter; it is a formal audit report on internal controls. Therefore, the document fits the category of Audit Report / Information (AR).
2024-04-25 Chinese
普莱柯关于2023年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from 普莱柯生物工程股份有限公司 regarding the 2023年度利润分配预案 (2023 annual profit distribution plan). It details the dividend per share, total dividend amount, and the decision-making process including board and supervisory committee approvals. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related shareholder meeting submission. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders. The document length is 1633 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is DIV with high confidence.
2024-04-25 Chinese
普莱柯非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Regulatory Filings
2024-04-25 Chinese
普莱柯关于第五届监事会第七次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of resolutions passed at the Supervisory Board meeting of 普莱柯生物工程股份有限公司 on April 25, 2023. It lists multiple agenda items including approval of the 2023 annual report, supervisory board work report, internal control evaluation report, financial statements, profit distribution plan, and other related proposals. However, the document itself does not contain the full reports or detailed financial data but refers to the Shanghai Stock Exchange website for the full content. The document is a meeting resolution announcement rather than the actual annual report or financial statements. It also mentions that these proposals will be submitted to the shareholders' meeting for approval. Given the nature of the document as a formal announcement of meeting resolutions and voting results, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2219 characters), and it does not contain the full reports, so it is not the report itself but an announcement of decisions made. Therefore, the correct classification is DVA with high confidence.
2024-04-25 Chinese
普莱柯2023年度募集资金存放与使用情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the storage and usage of funds raised by the company in 2023. It includes specifics on the amount raised, usage of funds, management of funds, investment projects, cash management, and compliance with regulatory guidelines. It references regulatory approvals, audit reports by an accounting firm, and opinions from the sponsor institution. The document is titled as an announcement and contains detailed financial and operational data related to the use of raised capital. This fits the category of a Capital/Financing Update (CAP), as it focuses on fundraising, capital usage, and related financial management rather than a full annual report or audit report. The document length is sufficient and contains substantive financial data about capital usage, not just an announcement of a report publication or a certification. Therefore, the best classification is CAP with high confidence.
2024-04-25 Chinese
普莱柯关于2023年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the 2023年度计提资产减值准备 (2023 annual asset impairment provision). It details the amounts of credit impairment losses and asset impairment losses recognized for the year ending December 31, 2023. The announcement includes specific figures, accounting policies referenced (Enterprise Accounting Standards), and mentions that the impairment provision has been audited by an accounting firm. The document is relatively short (1670 characters) and focuses on a specific accounting adjustment rather than presenting a full financial report or comprehensive financial statements. It is an official announcement of a specific financial event (asset impairment provision) rather than a full annual report or interim report. This type of announcement fits best under Regulatory Filings (RNS), as it is a regulatory disclosure about a financial matter but not a full report or earnings release. It is not a certification letter, nor a full audit report, nor a management discussion, nor a capital update. Therefore, the classification is RNS with high confidence.
2024-04-25 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.